Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells

Fertility and Sterility

Volumn 91, Issue 5 SUPPL., 2009, Pages 2142-2147

  Wu, Yan ^a   Guo, Sun Wei ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cell line; endometriosis; endometriotic cell; epigenetics; PPAR ; RXR; TSA

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRICHOSTATIN A;

ARTICLE; CELL PROLIFERATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOMETRIOSIS; ENDOMETRIUM CELL; EPIGENETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STROMA CELL; WESTERN BLOTTING;

CELL DIVISION; CELL LINE; ENDOMETRIUM; ESTRADIOL; FEMALE; HUMANS; NICOTINIC ACIDS; PPAR GAMMA; PROGESTERONE; RETINOID X RECEPTORS; STROMAL CELLS; TETRAHYDRONAPHTHALENES; TETRAZOLIUM SALTS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 65049092141     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.04.012     Document Type: Article

References (65)

1. Giudice L.C., and Kao L.C. Endometriosis. Lancet 364 (2004) 1789-1799
2. Wheeler J.M., and Malinak L.R. Recurrent endometriosis: incidence, management, and prognosis. Am J Obstet Gynecol 146 (1983) 247-253
3. Waller K.G., and Shaw R.W. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 59 (1993) 511-515
4. Kiilholma P., Tuimala R., Kivinen S., Korhonen M., and Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril 64 (1995) 903-908
5. Lessey B.A. Medical management of endometriosis and infertility. Fertil Steril 73 (2000) 1089-1096
6. Bulun S.E., Lin Z., Imir G., Amin S., Demura M., Yilmaz B., et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57 (2005) 359-383
7. Nothnick W.B., and D'Hooghe T.M. Medical management of endometriosis: novel targets and approaches towards the development of future treatment regimes. Gynecol Obstet Invest 55 (2003) 189-198
8. Fedele L., and Berlanda N. Emerging drugs for endometriosis. Expert Opin Emerg Drugs 9 (2004) 167-177
9. Guo S.W. Nuclear factor-kappaB (NF-κB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large?. Gynecol Obestet Invest 63 (2006) 71-97
10. Halme J., White C., Kauma S., Estes J., and Haskill S. Peritoneal macrophages from patients with endometriosis release growth factor activity in vitro. J Clin Endocrinol Metab 66 (1988) 1044-1049
11. Halme J., Becker S., and Haskill S. Altered maturation and function of peritoneal macrophages: possible role in pathogenesis of endometriosis. Am J Obstet Gynecol 156 (1987) 783-789
12. Harada T., Enatsu A., Mitsunari M., Nagano Y., Ito M., Tsudo T., et al. Role of cytokines in progression of endometriosis. Gynecol Obstet Invest 47 Suppl 1 (1999) 34-40
13. Taylor R.N., Ryan I.P., Moore E.S., Hornung D., Shifren J.L., and Tseng J.F. Angiogenesis and macrophage activation in endometriosis. Ann NY Acad Sci 828 (1997) 194-207
14. Schoonjans K., Martin G., Staels B., and Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8 (1997) 159-166
15. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem 43 (2000) 527-550
16. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
17. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
18. Schoonjans K., and Auwerx J. Thiazolidinediones: an update. Lancet 355 (2000) 1008-1010
19. Pritts E.A., Zhao D., Ricke E., Waite L., and Taylor R.N. PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab 87 (2002) 1841-1844
20. Wanichkul T., Han S., Huang R.P., and Sidell N. Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril 79 Suppl 1 (2003) 763-769
21. Akoum A., Lemay A., and Maheux R. Estradiol and interleukin-1beta exert a synergistic stimulatory effect on the expression of the chemokine regulated upon activation, normal T cell expressed, and secreted in endometriotic cells. J Clin Endocrinol Metab 87 (2002) 5785-5792
22. Pritts E.A., Zhao D., Sohn S.H., Chao V.A., Waite L.L., and Taylor R.N. Peroxisome proliferator-activated receptor-gamma ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element. Fertil Steril 80 (2003) 415-420
23. Aytan H., Caliskan A.C., Demirturk F., Aytan P., and Koseoglu D.R. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model. Aust NZ J Obstet Gynaecol 47 (2007) 321-325
24. Lebovic D.I., Kir M., and Casey C.L. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 82 Suppl 3 (2004) 1008-1013
25. Demirturk F., Aytan H., Caliskan A.C., Aytan P., and Koseoglu D.R. Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 13 (2006) 58-62
26. Lebovic D.I., Mwenda J.M., Chai D.C., Mueller M.D., Santi A., Fisseha S., et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 88 Suppl (2007) 1108-1119
27. Hornung D., Chao V.A., Vigne J.L., Wallwiener D., and Taylor R.N. Thiazolidinedione inhibition of peritoneal inflammation. Gynecol Obstet Invest 55 (2003) 20-24
28. Demirturk F., Aytan H., Caliskan A., Aytan P., Yener T., Koseoglu D., et al. The effect of rosiglitazone in the prevention of intra-abdominal adhesion formation in a rat uterine horn model. Hum Reprod 21 (2006) 3008-3013
29. Guo S.W., and Olive D.L. Two unsuccessful clinical trials on endometriosis and a few lessons learned. Gynecol Obstet Invest 64 (2007) 24-35
30. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84 (2001) 1424-1431
31. Voskoglou-Nomikos T., Pater J.L., and Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9 (2003) 4227-4239
32. Meade E.A., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 274 (1999) 8328-8334
33. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
34. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
35. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
36. Agic A., Xu H., Altgassen C., Noack F., Wolfler M.M., Diedrich K., et al. Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod Sci 14 (2007) 486-497
37. Sawatsri S., Desai N., Rock J.A., and Sidell N. Retinoic acid suppresses interleukin-6 production in human endometrial cells. Fertil Steril 73 (2000) 1012-1019
38. Bain D.L., Heneghan A.F., Connaghan-Jones K.D., and Miura M.T. Nuclear receptor structure: implications for function. Annu Rev Physiol 69 (2007) 201-220
39. Wu Y., Strawn E., Basir Z., Halverson G., and Guo S.W. Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in women with endometriosis. Fertil Steril 87 (2007) 24-32
40. Wu Y., Halverson G., Basir Z., Strawn Y., Yan P., and Guo S.W. Aberrant methylation at HOXA10 may be responsible for Its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol 192 (2005) 371-380
41. Wu Y., Strawn E., Basir Z., Halverson G., and Guo S.W. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics 1 (2006) 106-111
42. Wu Y., and Guo S.W. Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 62 (2006) 193-205
43. Wu Y., and Guo S.W. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 137 (2008) 198-203
44. Wu Y., and Guo S.W. Suppression of IL-1β-induced COX-2 expression by trischotatin A (TSA) in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 135 (2007) 88-93
45. Wu Y., Starzinski-Powitz A., Guo S.W., and Trichostatin A. a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci 14 (2007) 374-382
46. Krikun G., Mor G., Alvero A., Guller S., Schatz F., Sapi E., et al. A novel immortalized human endometrial stromal cell line with normal progestational response. Endocrinology 145 (2004) 2291-2296
47. Zeitvogel A., Baumann R., and Starzinski-Powitz A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 159 (2001) 1839-1852
48. Strakova N., Ehrmann J., Bartos J., Malikova J., Dolezel J., and Kolar Z. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 52 (2005) 126-136
49. Qin C., Burghardt R., Smith R., Wormke M., Stewart J., and Safe S. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 63 (2003) 958-964
50. Fan W., Yanase T., Morinaga H., Mu Y.M., Nomura M., Okabe T., et al. Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-κB. Endocrinology 146 (2005) 85-92
51. Winnett G., van Hagen D., and Schrey M. Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy. Int J Cancer 103 (2003) 600-605
52. Andrews W.J., Winnett G., Rehman F., Shanmugasundaram P., Hagen D., and Schrey M.P. Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production. J Steroid Biochem Mol Biol 94 (2005) 159-165
53. Yanase T., Mu Y.M., Nishi Y., Goto K., Nomura M., Okabe T., et al. Regulation of aromatase by nuclear receptors. J Steroid Biochem Mol Biol 79 (2001) 187-192
54. Mu Y.M., Yanase T., Nishi Y., Takayanagi R., Goto K., and Nawata H. Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells. Mol Cell Endocrinol 181 (2001) 239-248
55. Li M.Y., Deng H., Zhao J.M., Dai D., and Tan X.Y. PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol 9 (2003) 1220-1226
56. Cuzzocrea S., Pisano B., Dugo L., Ianaro A., Maffia P., Patel N.S., et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483 (2004) 79-93
57. Sanchez-Hidalgo M., Martin A.R., Villegas I., and Alarcon De La Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 69 (2005) 1733-1744
58. Planaguma A., Claria J., Miquel R., Lopez-Parra M., Titos E., Masferrer J.L., et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARγ activation. FASEB J 19 (2005) 1120-1122
59. Lappas M., Permezel M., and Rice G.E. Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2. Endocrinology 146 (2005) 3334-3342
60. Mangelsdorf D.J., Ong E.S., Dyck J.A., and Evans R.M. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 345 (1990) 224-229
61. Zhang X.K., Hoffmann B., Tran P.B., Graupner G., and Pfahl M. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 355 (1992) 441-446
62. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., and Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90 (1993) 2160-2164
63. Boehm M.F., Zhang L., Zhi L., McClurg M.R., Berger E., Wagoner M., et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 38 (1995) 3146-3155
64. Duvic M., Hymes K., Heald P., Breneman D., Martin A.G., Myskowski P., et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (2001) 2456-2471
65. Gottardis M.M., Bischoff E.D., Shirley M.A., Wagoner M.A., Lamph W.W., and Heyman R.A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56 (1996) 5566-5570